FGFR Inhibitors: Best Practices for Managing Treatment and Treatment-Related Adverse Events - Episode 13
FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life
Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
This is a video synopsis/summary of an OncLive Insights involving Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.
Stomatitis (mouth sores) is a common adverse effect of FGFR inhibitors such as pemigatinib and futibatinib. Preventative strategies include addressing preexisting dental issues beforehand starting treatment, reducing oral bacteria load through frequent mouth rinsing and gentle brushing, and avoiding irritating foods. If stomatitis develops, coating agents such as sucralfate or compounded “magic mouthwash” rinses with anesthetics/analgesics can provide symptom relief. Prompt dental referral may also help manage significant symptoms. Dry mouth is another problematic FGFR inhibitor adverse effect. Patients should maintain hydration and use water-soluble lubricants such as Biotene products. Dexamethasone elixir can also treat severe symptoms. Good oral hygiene and proactive steps are key to reducing impact on quality of life from stomatitis and dry mouth with FGFR inhibitor therapy.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.